Suggestions
Ashu Singhal
Co-Founder and President at Benchling
Ashu Singhal is the Co-Founder and President of Benchling, a company he co-founded in 2014. Benchling is a software platform designed to accelerate life sciences research and development (R&D) by streamlining data management and reducing reliance on outdated systems. Singhal's vision for Benchling emphasizes making research processes more efficient and accessible, allowing scientists to focus on innovation rather than administrative burdens.1
Professional Background
Before establishing Benchling, Singhal held several notable positions:
- Staff Software Engineer at Twitter (2012-2014): He was involved in designing and developing core infrastructure for Twitter Ads, particularly focusing on big data systems for campaign analytics and forecasting.
- Co-founder of Hotspots.io (2011-2012): This startup, which focused on real-time trend prediction based on social media data, was acquired by Twitter.
- Undergraduate Researcher at MIT CSAIL and MIT Media Lab: He worked on projects related to computational biology and synthetic neurobiology during his time at MIT.1
Education
Ashu Singhal earned his degree from the Massachusetts Institute of Technology (MIT), where he was involved in various research initiatives that laid the foundation for his later work in technology and life sciences.1
Current Role
As President of Benchling, Singhal continues to lead efforts to innovate within the life sciences sector, aiming to enhance the tools available for researchers globally.1 His leadership is crucial in driving the company's mission to transform how scientific research is conducted through advanced software solutions.
Highlights
About 10 years ago, Saji and I started Benchling because we believed in the promise of modern science to change the world — and we wanted to accelerate the pace of that progress. That’s what #TeamScience means to me.
Hear directly from Benchlings to understand why #TeamScience is such a central part of our mission and culture. https://lnkd.in/gGcc8xp6
We’re at an RNA tipping point, and COVID vaccines are just the beginning. With 44% of top 50 global biopharma companies now involved in RNA work, the industry is increasing its focus on RNA-based therapies. The potential for RNA to treat (and even cure) a wide range of diseases is enormous.
Today I’m pleased to share the launch of our new RNA capabilities — making the Benchling R&D Cloud the first complete solution for RNA R&D. Whether it’s a new mRNA vaccine or RNA cancer treatment, our customers are working towards incredible breakthroughs and we’re proud to support RNA R&D with modern software. https://lnkd.in/gceNpfMn
Learn more about our latest product updates: https://lnkd.in/gCHNM_PY
